Nottingham, UK – Upperton Pharma Solutions has reached a major milestone in its expansion strategy, securing official approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to begin sterile manufacturing operations at its new Trent Gateway facility in Nottingham. The regulatory green light, which grants a variation to the company’s existing Manufacturing and Importation Authorization for Investigational Medicinal Products (MIA(IMP)) license, positions Upperton as a key player in the UK’s evolving landscape of sterile pharmaceutical development.
The new 7,000 sq. ft. facility is among the first of its kind in the UK to be fully aligned with the revised EU GMP Annex 1 requirements. By embedding a rigorous Contamination Control Strategy from the initial design phase through to final qualification, Upperton has created a sophisticated environment capable of handling complex, small-batch drug product manufacturing.
“Securing this license is a major achievement for Upperton and reflects the dedication and technical expertise of our team,” said CEO Nikki Whitfield. “The revised Annex 1 framework has significantly raised expectations across sterile manufacturing, and we are proud to have developed a facility that places contamination control, quality, and patient safety at the center of its design.”
With this authorization now in effect, the company is set to begin Good Manufacturing Practice (GMP) production of sterile investigational medicinal products destined for early-phase clinical trials. The site features advanced infrastructure, including Grade A isolator environments, vaporized hydrogen peroxide (VHP) bio-decontamination, and Pre-Use Post Sterilization Integrity Testing (PUPSIT). These high-spec systems are designed to minimize operator intervention and maximize the safety of both aseptic and terminally sterilized drug products.
The facility’s commissioning addresses a critical bottleneck for emerging biotech innovators who often struggle to find responsive, small-scale sterile fill-finish services for complex biologics and small molecule programs. By integrating this new capacity into its existing 50,000 sq. ft. campus, Upperton is now able to offer a comprehensive “one-site” model. This allows clients to transition seamlessly from early-stage formulation development and analytical testing to full GMP sterile manufacture without the need to switch vendors.
Industry experts anticipate that this expanded capability will significantly streamline the path to clinical trials, enabling biotech firms to make faster, more informed decisions regarding manufacturing routes and product presentations. As clinical supply timelines remain a primary pressure point for new drug development, the availability of flexible, UK-based sterile manufacturing is expected to be a vital asset for the sector.
With the Trent Gateway facility now operational, Upperton is actively opening its doors to partners looking for high-quality, flexible support for first-in-human and early-phase clinical studies, reinforcing Nottingham’s standing as a premier hub for life sciences innovation.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
